What Has Been the Progress and Growth of the Chronic Myeloid Leukemia Treatment Market in Recent Years?
The chronic myeloid leukemia treatment market has seen considerable growth due to a variety of factors.
• In recent times, there has been robust growth in the market size of chronic myeloid leukemia treatments. The market is projected to escalate from $9.2 billion in 2024 to $9.76 billion in 2025, with a compound annual growth rate (CAGR) of 6.2%.
The substantial growth in the historical span can be accounted for by various factors such as an increase in cases of chronic myeloid leukemia, enhanced understanding of cancer treatment, government initiatives, and an upswing in research and development activities directed towards treatments for chronic myeloid leukemia.
What Can Be Expected from the Chronic Myeloid Leukemia Treatment Market Size?
The chronic myeloid leukemia treatment market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the market size for chronic myeloid leukemia treatment is projected to witness robust growth. The market is anticipated to swell to a value of $13.12 billion by 2029 with a compound annual growth rate (CAGR) of 7.7%.
Factors contributing to this growth over the forecast period include increasing demand for more enduring and efficient treatments, escalating healthcare expenditures, investments funnelled into chronic myeloid leukemia treatments, and the rise of personalized medicine. Key trends impacting the future of this market comprise improved diagnosis and screening methods, breakthrough treatments for chronic myeloid leukemia, the creation of targeted therapies, advancements in early diagnostic and screening procedures, and evolving monitoring technologies.
What Are the Critical Driver Fuelling The Chronic Myeloid Leukemia Treatment Market's Growth?
The growing number of myeloid leukemia cases is predicted to stimulate the advancement of the chronic myeloid leukemia (CML) treatment market. Myeloid leukemia, a cancer emerging from the bone marrow that disrupts blood cell production, is addressed by CML treatment, which focuses on improving bone marrow function by tackling leukemia's primary source. This treatment reduces complications associated with low blood cell counts, decreases the necessity for chemotherapy and transplant procedures and enhances survival rates in individuals with myeloid leukemia. For example, the American Cancer Society noted in January 2023 that there were approximately 20,380 cases and 11,310 deaths due to acute myeloid leukemia (AML) in adults that year. Consequently, the escalating myeloid leukemia cases fuel the expansion of the chronic myeloid leukemia (CML) treatment market. The escalation of chromosome abnormalities is foreseen to fuel the growth of the chronic myeloid leukemia (CML) treatment market in the years to come. Chromosome abnormalities pertain to numerical or structural anomalies present in a person's chromosomes, which are strands inside cells that carry genetic data. Those with specific chromosomal abnormalities might face a bleak prognosis and require extensive treatment, like CML. For instance, a study in Saudi Arabia, cited by the US-based National Library of Medicine (NLM), a biomedical informatics and computational health data science research, found chromosome abnormalities in 59 newborns with congenital anomalies (39.3%), representing 2.3% of total newborn intensive care unit (NICU) admissions. Thus, the rising incidences of chromosome abnormalities are driving the growth of the chronic myeloid leukemia (CML) treatment market.
How Is The Chronic Myeloid Leukemia Treatment Market segmented?
The chronic myeloid leukemia treatment market covered in this report is segmented –
1) By Type: Targeted Therapy, Chemotherapy, Radiation Therapy, Splenectomy, Stem Cell Transplant
2) By Route of Administration: Oral, Parenteral, Other Route of Administrations
3) By End-User: Hospitals, Specialty Clinics, Other End-Users
Subsegments:
1) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), Monoclonal Antibodies
2) By Chemotherapy: Combination Chemotherapy, Single-Agent Chemotherapy
3) By Radiation Therapy: External Beam Radiation Therapy, Total Body Irradiation
4) By Splenectomy: Open Splenectomy, Laparoscopic Splenectomy
5) By Stem Cell Transplant: Autologous Stem Cell Transplant, Allogeneic Stem Cell Transplant
Pre-Book The Chronic Myeloid Leukemia Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Chronic Myeloid Leukemia Treatment Market?
Leading firms within the chronic myeloid leukemia (CML) treatment sphere are focusing their efforts on innovative product development to maintain market dominance. Take for example, Precipio, Inc., a cancer diagnostics company based in the US, which, in August 2023, unveiled the BCR-ABL 2.0 Panel for CML. This advanced instrument detects the BCR-ABL1 gene, a crucial step in diagnosing chronic myeloid leukemia (CML). Considered the most sophisticated BCR-ABL panel to date, it offers comprehensive coverage, simplified workflow, and cost reduction, all while improving patient care. Moreover, it can detect the ABL1 mutation, thereby eliminating the requirement for a secondary BCR-ABL1 gene test, ultimately delivering highly accurate results.
Who Are the Key Players In The Chronic Myeloid Leukemia Treatment Market?
Major companies operating in the chronic myeloid leukemia treatment market are:
• Pfizer Inc.
• Johnson and Johnson Limited
• F. Hoffmann-La Roche AG
• AbbVie Inc.
• Novartis AG
• Merck and Co. Inc.
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• GSK PLC
• Takeda Pharmaceutical Company Limited
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Otsuka Holdings Co Ltd.
• Mylan N.V.
• Astellas Pharma IncIncyte Corporation
• Lupin Limited
• Seattle Genetics Inc.
• Innovent Biologics Inc.
• Xencor Inc.
• ARIAD Pharmaceuticals Inc.
• Celon Laboratories Pvt. Ltd.
What Is The Most Dominant Region In The Chronic Myeloid Leukemia Treatment Market?
North America was the largest region in the chronic myeloid leukemia treatment market in 2024. The regions covered in chronic myeloid leukemia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
